Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan · Delayed Price · Currency is TWD 100.50
+2.50 (2.55%)
May 29, 2026, 1:30 PM CST
TPE:6919 Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -284.11 | -351.92 | -588.83 | -488.46 | -286.16 | -224.29 |
Depreciation & Amortization | 31.17 | 30.66 | 29.51 | 27.87 | 25.34 | 23.28 |
Loss (Gain) From Sale of Assets | - | - | - | - | 0.11 | - |
Stock-Based Compensation | 171.49 | 122.1 | 65.05 | 22.98 | 19.71 | 74.76 |
Other Operating Activities | -265.83 | -187.28 | -6.69 | -0.35 | -0.36 | -3.27 |
Change in Accounts Receivable | 0 | -1.31 | 2.71 | -4.77 | -3.12 | - |
Change in Inventory | 3.58 | -0.02 | -1.84 | 1.78 | -2.76 | 2.48 |
Change in Accounts Payable | -1.51 | 0.29 | -0.73 | -0.83 | 2.21 | -0.41 |
Change in Unearned Revenue | 3.12 | -2.54 | 2.59 | -3.47 | 4.5 | - |
Change in Other Net Operating Assets | 11.59 | -35.88 | -24.08 | 21.32 | -2.22 | 16.77 |
Operating Cash Flow | -330.5 | -425.9 | -522.31 | -423.94 | -242.76 | -110.7 |
Capital Expenditures | -17.51 | -16.53 | -10 | -8.6 | -14.16 | -14.9 |
Sale of Property, Plant & Equipment | - | - | - | - | 0 | - |
Sale (Purchase) of Intangibles | -1.27 | -0.61 | -1.09 | -1.09 | - | - |
Investment in Securities | -6,394 | -5,603 | -2,478 | 166.78 | -456.18 | - |
Other Investing Activities | -17.33 | -4.61 | - | 0.01 | -0.2 | - |
Investing Cash Flow | -6,430 | -5,624 | -2,489 | 157.09 | -470.54 | -14.9 |
Long-Term Debt Repaid | - | -8.88 | -8.58 | -8.22 | -12.6 | -93.98 |
Total Debt Repaid | -8.92 | -8.88 | -8.58 | -8.22 | -12.6 | -93.98 |
Net Debt Issued (Repaid) | -8.92 | -8.88 | -8.58 | -8.22 | -12.6 | -93.98 |
Issuance of Common Stock | 88.66 | 44.29 | 6,499 | 3,042 | 784.32 | 720.88 |
Repurchase of Common Stock | -154.52 | -154.52 | - | - | - | -0.09 |
Financing Cash Flow | -74.78 | -119.11 | 6,491 | 3,034 | 771.72 | 626.81 |
Foreign Exchange Rate Adjustments | 76.7 | 52.24 | -0.11 | 0.32 | 1.73 | 0.14 |
Net Cash Flow | -6,758 | -6,117 | 3,479 | 2,767 | 60.15 | 501.35 |
Free Cash Flow | -348.01 | -442.43 | -532.31 | -432.54 | -256.93 | -125.6 |
Free Cash Flow Margin | -914.89% | -1163.16% | -1197.97% | -1111.01% | -2004.12% | -1017.90% |
Free Cash Flow Per Share | -0.23 | -0.29 | -0.37 | -0.35 | -0.22 | -0.14 |
Cash Interest Paid | 0.11 | 0.16 | 0.33 | 0.5 | 0.67 | 6.18 |
Cash Income Tax Paid | - | - | - | - | - | 0.03 |
Levered Free Cash Flow | -323.46 | -401.63 | -391.26 | -266.4 | -171.06 | -74 |
Unlevered Free Cash Flow | -323.39 | -401.53 | -391.05 | -266.09 | -170.65 | -72.19 |
Change in Working Capital | 16.78 | -39.46 | -21.35 | 14.03 | -1.4 | 18.84 |